Antigen-specific TH17 cells offset the age-related decline in durable T cell immunity.

CD8+ T cells showed profound age-sensitive changes including memory subset shifts, reduced T cell receptor diversity, and loss of stem-like features.

• Age-related changes in CD8+ T cells were contrasted between adults vaccinated at young age (<20 years) versus older age (>50 years).
• Memory subset composition shifted with age in VZV-specific CD8+ T cells.
• TCR diversity was reduced in older adults' VZV-specific CD8+ T cells.
• Stem-like features were lost in CD8+ T cells from older vaccinated adults.
• These defects were not restored by vaccination with the adjuvanted component vaccine.

VZV-specific CD4+ T cells did not exhibit the same profound age-sensitive changes seen in CD8+ T cells.

• Unlike CD8+ T cells, CD4+ T cells were contrasted between young and older vaccinated individuals.
• The paper specifically states 'Unlike VZV-specific CD4+ T cells, CD8+ T cells exhibited profound age-sensitive changes.'
• This differential age sensitivity between CD4+ and CD8+ compartments was a key distinguishing finding.

The adjuvanted component vaccine (Shingrix) selectively enhanced TH17 CD4+ T cells in older adults.

• Vaccination of older adults with the adjuvanted vaccine did not restore CD8+ T cell defects.
• The adjuvanted vaccine selectively enhanced T helper 17 (TH17) CD4+ T cells.
• This enhancement was specific to the adjuvanted component vaccine, which confers durable protection in older adults.
• The live-attenuated vaccine confers durable protection only when given at young age, not in older adults.

The adjuvanted vaccine prevented conversion of TH17 cells into regulatory T cells, likely through lipid metabolic regulation.

• TH17 cells were found to be at risk of converting into regulatory T cells (Tregs).
• The adjuvanted vaccine prevented this TH17-to-Treg conversion.
• Lipid metabolic regulation was identified as the likely mechanism preventing this conversion.
• This finding links metabolic programming to the maintenance of TH17 identity in the context of aging.

Durable vaccine efficacy in aging relies on antigen-specific TH17 cells compensating for CD8+ T cell defects.

• The study contrasted two vaccines: a live-attenuated vaccine (durable only in young) and an adjuvanted component vaccine (durable in older adults).
• The mechanism of durable protection in older adults was attributed to TH17 cell enhancement rather than CD8+ T cell restoration.
• TH17 cells were found to functionally offset age-related CD8+ T cell deficiencies.
• This represents a compensatory immunological mechanism specific to the adjuvanted vaccine formulation.

The two VZV vaccines differ in their ability to confer durable protection depending on age at vaccination.

• The live-attenuated vaccine confers durable protection only when given at young age (<20 years).
• The adjuvanted component vaccine elicits long-lasting immunity in older adults (>50 years).
• This age-dependent difference in vaccine efficacy formed the basis for comparing immune memory mechanisms.
• The study design used these two vaccines as contrasting models to uncover mechanisms of long-lasting immune memory.